Multi-level quality improvement strategies to optimize HPV vaccination starting at the 9-year well child visit: Success stories from two private pediatric clinics.

IF 4.8 4区 医学 Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-02-16 DOI:10.1080/21645515.2022.2163807
Sherri Zorn, Gabrielle Darville-Sanders, Thuy Vu, Amy Carter, Katie Treend, Char Raunio, Anjali Vasavada
{"title":"Multi-level quality improvement strategies to optimize HPV vaccination starting at the 9-year well child visit: Success stories from two private pediatric clinics.","authors":"Sherri Zorn, Gabrielle Darville-Sanders, Thuy Vu, Amy Carter, Katie Treend, Char Raunio, Anjali Vasavada","doi":"10.1080/21645515.2022.2163807","DOIUrl":null,"url":null,"abstract":"<p><p>HPV vaccination rates remain far below goal, leaving many adolescents unprotected against future HPV-related cancers. Starting HPV vaccine at age 9 may improve timely preteen vaccination. The \"HPV Vax at 9\" Quality Improvement intervention paired HPV vaccination with 9- and 10-year well child visits and was piloted at two pediatric clinics (<i>n</i> = 9 sites) in Washington between 2018 and 2022. Supporting interventions included standardized immunization schedule posters in exam rooms, electronic medical record supports, provider and staff training, strong provider recommendations, printed educational resources, and peer-to-peer champion coaching. Provider and clinic acceptance was high with HPV vaccine administration occurring at 68-86% of the 9- and 10-year well child visits. During the first year, HPV initiation rates at age 9-10 increased by 30% or more at each clinic. Sustained improvements in initiation and series completion were seen with completion at age 11-12 rising as much as 40% from 22 to 62%. Downward pressure of the COVID-19 pandemic on HPV vaccination rates was mitigated. Pairing HPV vaccine with 9- and 10-year well child visits, posting the standardized immunization schedule, and instituting EMR supports for HPV at 9 may be effective and sustainable strategies to simplify clinic workflows and increase timely HPV vaccination.</p>","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2163807"},"PeriodicalIF":4.8000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/42/KHVI_19_2163807.PMC10054168.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21645515.2022.2163807","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

HPV vaccination rates remain far below goal, leaving many adolescents unprotected against future HPV-related cancers. Starting HPV vaccine at age 9 may improve timely preteen vaccination. The "HPV Vax at 9" Quality Improvement intervention paired HPV vaccination with 9- and 10-year well child visits and was piloted at two pediatric clinics (n = 9 sites) in Washington between 2018 and 2022. Supporting interventions included standardized immunization schedule posters in exam rooms, electronic medical record supports, provider and staff training, strong provider recommendations, printed educational resources, and peer-to-peer champion coaching. Provider and clinic acceptance was high with HPV vaccine administration occurring at 68-86% of the 9- and 10-year well child visits. During the first year, HPV initiation rates at age 9-10 increased by 30% or more at each clinic. Sustained improvements in initiation and series completion were seen with completion at age 11-12 rising as much as 40% from 22 to 62%. Downward pressure of the COVID-19 pandemic on HPV vaccination rates was mitigated. Pairing HPV vaccine with 9- and 10-year well child visits, posting the standardized immunization schedule, and instituting EMR supports for HPV at 9 may be effective and sustainable strategies to simplify clinic workflows and increase timely HPV vaccination.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
从9岁健康儿童就诊开始,优化HPV疫苗接种的多层次质量改进策略:来自两家私立儿科诊所的成功案例。
HPV疫苗接种率仍远低于目标,使许多青少年无法预防未来与HPV相关的癌症。从9岁开始接种HPV疫苗可以提高学龄前疫苗接种的及时性。“9岁时的HPV Vax”质量改善干预措施将HPV疫苗接种与9岁和10岁健康儿童就诊配对,并在两个儿科诊所进行了试点(n = 9个地点)。支持性干预措施包括在检查室张贴标准化免疫接种时间表海报、电子病历支持、提供者和工作人员培训、强有力的提供者建议、印刷教育资源和同伴冠军辅导。提供者和诊所的接受率很高,在9岁和10岁健康儿童就诊中,接种HPV疫苗的比例为68-86%。在第一年,9-10岁的HPV发病率在每个诊所增加了30%或更多。启动和系列完成率持续改善,11-12岁的完成率从22%上升到62%,高达40%。新冠肺炎疫情对HPV疫苗接种率的下行压力得到缓解。将HPV疫苗与9岁和10岁健康儿童就诊配对,公布标准化免疫计划,并在9岁时为HPV建立EMR支持,可能是简化临床工作流程和增加及时HPV疫苗接种的有效和可持续的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
自引率
8.30%
发文量
0
审稿时长
1 months
期刊介绍: (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
期刊最新文献
Emerging insights into thyroid cancer from immunotherapy perspective: A bibliometric analysis. COBRA N2 NA vaccines induce protective immune responses against influenza viral infection. Uptake, adverse effect, and associated factors of COVID-19 vaccine among those living with human immunodeficiency virus, at Bole sub-city health facility Addis Ababa, Ethiopia Immunotherapy and delivery systems for melanoma Human vaccines and immunotherapeutics: News August 2024
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1